Machine Learning-Based Perivascular Space Volumetry in Alzheimer Disease

Artificial Intelligence in Psychiatry: A Review of Biological and Behavioral Data Analyses

Artificial intelligence (AI) has emerged as a transformative force in psychiatry, improving diagnostic precision, treatment personalization, and early intervention through advanced data analysis techniques. This review explores recent advancements in AI applications within psychiatry, focusing on EEG and ECG data analysis, speech analysis, natural language processing (NLP), blood biomarker integration, and social media data utilization. EEG-based models have significantly enhanced the detection of disorders such as depression and schizophrenia through spectral and connectivity analyses. ECG-based approaches have provided insights into emotional regulation and stress-related conditions using heart rate variability. Speech analysis frameworks, leveraging large language models (LLMs), have improved the detection of cognitive impairments and psychiatric symptoms through nuanced linguistic feature extraction. Meanwhile, blood biomarker analyses have deepened our understanding of the molecular underpinnings of mental health disorders, and social media analytics have demonstrated the potential for real-time mental health surveillance. Despite these advancements, challenges such as data heterogeneity, interpretability, and ethical considerations remain barriers to widespread clinical adoption. Future research must prioritize the development of explainable AI models, regulatory compliance, and the integration of diverse datasets to maximize the impact of AI in psychiatric care.

Machine learning-based identification and validation of immune-related biomarkers for early diagnosis and targeted therapy in diabetic retinopathy

The early diagnosis of diabetic retinopathy (DR) is challenging, highlighting the urgent need to identify new biomarkers. Immune responses play a crucial role in DR, yet there are currently no reports of machine learning (ML) algorithms being utilized for the development of immune-related molecular markers in DR. Based on the datasets GSE102485 and GSE160306, differentially expressed genes (DEGs) were screened using Weighted Gene Co-expression Network Analysis (WGCNA). Five ML algorithms including Bayesian, Learning Vector Quantization (LVQ), Wrapper (Boruta), Random Forest (RF), and Logistic Regression were employed to select immune-related genes associated with DR (DR.Sig). Seven ML algorithms including Naive Bayes (NB), RF, Support Vector Machine (SVM), AdaBoost Classification Trees (AdaBoost), Boosted Logistic Regressions (LogitBoost), K-Nearest Neighbors (KNN), and Cancerclass were utilized to construct a predictive model for DR. The relationship between DR.Sig genes and immune cells was analyzed using single-sample Gene Set Enrichment Analysis (ssGSEA). Additionally, drug sensitivity prediction of DR.Sig genes and molecular docking were performed. Through the utilization of 5 ML algorithms, 6 immune-related biomarkers closely related to the occurrence of DR were identified, including FCGR2B, CSRP1, EDNRA, SDC2, TEK, and CIITA. The DR predictive model constructed based on these 6 DR.Sig genes using the Cancerclass algorithm demonstrated superior predictive performance compared to 4 previously published DR-related biomarkers. In vivo and in vitro experiments also provided strong validation of the expression of the 6 genes in DR. Positive correlations were observed between these genes and 22 types of immune cells. Molecular docking results revealed that CSRP1, EDNRA, and TEK exhibited the highest affinities with the small molecule compounds etoposide, FR-139317, and camptothecin, respectively. The models constructed based on various ML algorithms can effectively predict the occurrence of DR events and hold potential for targeted drug therapies, providing a basis for the early diagnosis and targeted treatment of DR.